Story perspectives

FDA Fast-Tracks Nine Experimental Drugs for National Priorities

10/17/2025

26 5

Summary

Story summary

The U.S. Food and Drug Administration announced an initiative to expedite reviews for nine experimental drugs, prioritizing therapies aligned with U.S. national interests, as stated by the Trump administration.
The nine drugs include treatments for vaping addiction, deafness, and pancreatic cancer.
FDA Commissioner Dr. Marty Makary said approvals could occur within one to two months under the Commissioner’s National Priority Voucher program, which allows greater discretion in fast-tracking nine drugs.

1 of 1

Story summary

The U.S. Food and Drug Administration announced an initiative to expedite reviews for nine experimental drugs, prioritizing therapies aligned with U.S. national interests, as stated by the Trump administration.
The nine drugs include treatments for vaping addiction, deafness, and pancreatic cancer.
FDA Commissioner Dr. Marty Makary said approvals could occur within one to two months under the Commissioner’s National Priority Voucher program, which allows greater discretion in fast-tracking nine drugs.